Lifetime use of psychiatric medications and cognition at 43 years of age in schizophrenia in the Northern Finland Birth Cohort 1966
Abstract Background: Higher lifetime antipsychotic exposure has been associated with poorer cognition in schizophrenia. The cognitive effects of adjunctive psychiatric medications and lifetime trends of antipsychotic use remain largely unclear. We aimed to study how lifetime and current benzodiazepi...
Published in: | European Psychiatry |
---|---|
Main Authors: | , , , , , , , , , , , |
Other Authors: | , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Cambridge University Press (CUP)
2017
|
Subjects: | |
Online Access: | http://dx.doi.org/10.1016/j.eurpsy.2017.06.004 https://api.elsevier.com/content/article/PII:S0924933817329061?httpAccept=text/xml https://api.elsevier.com/content/article/PII:S0924933817329061?httpAccept=text/plain https://www.cambridge.org/core/services/aop-cambridge-core/content/view/S0924933800087575 |
id |
crcambridgeupr:10.1016/j.eurpsy.2017.06.004 |
---|---|
record_format |
openpolar |
spelling |
crcambridgeupr:10.1016/j.eurpsy.2017.06.004 2024-06-09T07:48:31+00:00 Lifetime use of psychiatric medications and cognition at 43 years of age in schizophrenia in the Northern Finland Birth Cohort 1966 Hulkko, A.P. Murray, G.K. Moilanen, J. Haapea, M. Rannikko, I. Jones, P.B. Barnett, J.H. Huhtaniska, S. Isohanni, M.K. Koponen, H. Jääskeläinen, E. Miettunen, J. Academy of Finland Sigrid Jusélius Foundation Brain & Behavior Research Foundation Jalmari and Rauha Ahokas Foundation Finnish Cultural Foundation Lapland Regional Fund Northern Finland Health Care Support Foundation scholarship Fund of the University of Oulu - Tyyni Tani Fund Foundation for Psychiatric Research Orion Research Foundation sr 2017 http://dx.doi.org/10.1016/j.eurpsy.2017.06.004 https://api.elsevier.com/content/article/PII:S0924933817329061?httpAccept=text/xml https://api.elsevier.com/content/article/PII:S0924933817329061?httpAccept=text/plain https://www.cambridge.org/core/services/aop-cambridge-core/content/view/S0924933800087575 en eng Cambridge University Press (CUP) https://www.cambridge.org/core/terms https://www.elsevier.com/tdm/userlicense/1.0/ European Psychiatry volume 45, page 50-58 ISSN 0924-9338 1778-3585 journal-article 2017 crcambridgeupr https://doi.org/10.1016/j.eurpsy.2017.06.004 2024-05-15T13:00:18Z Abstract Background: Higher lifetime antipsychotic exposure has been associated with poorer cognition in schizophrenia. The cognitive effects of adjunctive psychiatric medications and lifetime trends of antipsychotic use remain largely unclear. We aimed to study how lifetime and current benzodiazepine and antidepressant medications, lifetime trends of antipsychotic use and antipsychotic polypharmacy are associated with cognitive performance in midlife schizophrenia. Methods: Sixty participants with DSM-IV schizophrenia from the Northern Finland Birth Cohort 1966 were examined at 43 years of age with an extensive cognitive test battery. Cumulative lifetime and current use of psychiatric medications were collected from medical records and interviews. The associations between medication and principal component analysis-based cognitive composite score were analysed using linear regression. Results: Lifetime cumulative DDD years of benzodiazepine and antidepressant medications were not significantly associated with global cognition. Being without antipsychotic medication (for minimum 11 months) before the cognitive examination was associated with better cognitive performance ( P = 0.007) and higher lifetime cumulative DDD years of antipsychotics with poorer cognition ( P = 0.020), when adjusted for gender, onset age and lifetime hospital treatment days. Other lifetime trends of antipsychotic use, such as a long antipsychotic-free period earlier in the treatment history, and antipsychotic polypharmacy, were not significantly associated with cognition. Conclusions: Based on these naturalistic data, low exposure to adjunctive benzodiazepine and antidepressant medications does not seem to affect cognition nor explain the possible negative effects of high dose long-term antipsychotic medication on cognition in schizophrenia. Article in Journal/Newspaper Northern Finland Cambridge University Press European Psychiatry 45 50 58 |
institution |
Open Polar |
collection |
Cambridge University Press |
op_collection_id |
crcambridgeupr |
language |
English |
description |
Abstract Background: Higher lifetime antipsychotic exposure has been associated with poorer cognition in schizophrenia. The cognitive effects of adjunctive psychiatric medications and lifetime trends of antipsychotic use remain largely unclear. We aimed to study how lifetime and current benzodiazepine and antidepressant medications, lifetime trends of antipsychotic use and antipsychotic polypharmacy are associated with cognitive performance in midlife schizophrenia. Methods: Sixty participants with DSM-IV schizophrenia from the Northern Finland Birth Cohort 1966 were examined at 43 years of age with an extensive cognitive test battery. Cumulative lifetime and current use of psychiatric medications were collected from medical records and interviews. The associations between medication and principal component analysis-based cognitive composite score were analysed using linear regression. Results: Lifetime cumulative DDD years of benzodiazepine and antidepressant medications were not significantly associated with global cognition. Being without antipsychotic medication (for minimum 11 months) before the cognitive examination was associated with better cognitive performance ( P = 0.007) and higher lifetime cumulative DDD years of antipsychotics with poorer cognition ( P = 0.020), when adjusted for gender, onset age and lifetime hospital treatment days. Other lifetime trends of antipsychotic use, such as a long antipsychotic-free period earlier in the treatment history, and antipsychotic polypharmacy, were not significantly associated with cognition. Conclusions: Based on these naturalistic data, low exposure to adjunctive benzodiazepine and antidepressant medications does not seem to affect cognition nor explain the possible negative effects of high dose long-term antipsychotic medication on cognition in schizophrenia. |
author2 |
Academy of Finland Sigrid Jusélius Foundation Brain & Behavior Research Foundation Jalmari and Rauha Ahokas Foundation Finnish Cultural Foundation Lapland Regional Fund Northern Finland Health Care Support Foundation scholarship Fund of the University of Oulu - Tyyni Tani Fund Foundation for Psychiatric Research Orion Research Foundation sr |
format |
Article in Journal/Newspaper |
author |
Hulkko, A.P. Murray, G.K. Moilanen, J. Haapea, M. Rannikko, I. Jones, P.B. Barnett, J.H. Huhtaniska, S. Isohanni, M.K. Koponen, H. Jääskeläinen, E. Miettunen, J. |
spellingShingle |
Hulkko, A.P. Murray, G.K. Moilanen, J. Haapea, M. Rannikko, I. Jones, P.B. Barnett, J.H. Huhtaniska, S. Isohanni, M.K. Koponen, H. Jääskeläinen, E. Miettunen, J. Lifetime use of psychiatric medications and cognition at 43 years of age in schizophrenia in the Northern Finland Birth Cohort 1966 |
author_facet |
Hulkko, A.P. Murray, G.K. Moilanen, J. Haapea, M. Rannikko, I. Jones, P.B. Barnett, J.H. Huhtaniska, S. Isohanni, M.K. Koponen, H. Jääskeläinen, E. Miettunen, J. |
author_sort |
Hulkko, A.P. |
title |
Lifetime use of psychiatric medications and cognition at 43 years of age in schizophrenia in the Northern Finland Birth Cohort 1966 |
title_short |
Lifetime use of psychiatric medications and cognition at 43 years of age in schizophrenia in the Northern Finland Birth Cohort 1966 |
title_full |
Lifetime use of psychiatric medications and cognition at 43 years of age in schizophrenia in the Northern Finland Birth Cohort 1966 |
title_fullStr |
Lifetime use of psychiatric medications and cognition at 43 years of age in schizophrenia in the Northern Finland Birth Cohort 1966 |
title_full_unstemmed |
Lifetime use of psychiatric medications and cognition at 43 years of age in schizophrenia in the Northern Finland Birth Cohort 1966 |
title_sort |
lifetime use of psychiatric medications and cognition at 43 years of age in schizophrenia in the northern finland birth cohort 1966 |
publisher |
Cambridge University Press (CUP) |
publishDate |
2017 |
url |
http://dx.doi.org/10.1016/j.eurpsy.2017.06.004 https://api.elsevier.com/content/article/PII:S0924933817329061?httpAccept=text/xml https://api.elsevier.com/content/article/PII:S0924933817329061?httpAccept=text/plain https://www.cambridge.org/core/services/aop-cambridge-core/content/view/S0924933800087575 |
genre |
Northern Finland |
genre_facet |
Northern Finland |
op_source |
European Psychiatry volume 45, page 50-58 ISSN 0924-9338 1778-3585 |
op_rights |
https://www.cambridge.org/core/terms https://www.elsevier.com/tdm/userlicense/1.0/ |
op_doi |
https://doi.org/10.1016/j.eurpsy.2017.06.004 |
container_title |
European Psychiatry |
container_volume |
45 |
container_start_page |
50 |
op_container_end_page |
58 |
_version_ |
1801380286725881856 |